Hoffmann-la Roche

This study tested an eye injection called vamikibart in 256 people with uveitic macular edema, a condition where inflammation causes swelling in the back of the eye and blurs vision. Participants received either the drug or a sham procedure. The main goal was to see if more peopl…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This study followed 144 adults with chronic kidney disease (stages 3-4) who were not yet on dialysis and were already taking MIRCERA for anemia. Researchers tracked their hemoglobin levels and any changes in treatment over 12 months to see how well the drug works in everyday medi…

This phase 3 trial tested whether adding two immunotherapy drugs, atezolizumab and tiragolumab, to standard chemotherapy could help people with advanced esophageal cancer live longer. About 461 participants received either the immunotherapy combo plus chemo or a placebo plus chem…

This study tested whether a subcutaneous (under-the-skin) injection of the immunotherapy drug atezolizumab works as well as the standard intravenous (IV) infusion in people with advanced non-small cell lung cancer who had already tried platinum-based chemotherapy. The trial enrol…

This phase 3 study tested whether a combination of two targeted drugs, venetoclax and obinutuzumab, works better than standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who lack certain genetic mutations. The main go…

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and resea…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This phase 3 trial tested a small, refillable implant placed in the eye that continuously releases the drug ranibizumab to control diabetic retinopathy. The study enrolled 174 people with moderate-to-severe non-proliferative diabetic retinopathy but without swelling in the center…

This study looked at the long-term safety of faricimab, a drug injected into the eye, for people with wet age-related macular degeneration (AMD). Over 1,000 participants who completed earlier faricimab trials received personalized treatment intervals. The goal was to monitor eye …

This phase 3 trial tested whether combining two immunotherapy drugs, atezolizumab and tiragolumab, works better than the standard drug durvalumab in people with stage III lung cancer that cannot be removed by surgery. All 829 participants had already received chemotherapy and rad…

This phase 2 trial tested two new experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had stopped responding to chemotherapy. The drugs are designed to boost the immune system's ability t…

This phase 2 trial tested whether adding tiragolumab to atezolizumab (Tecentriq) helps shrink tumors better than atezolizumab alone in people with advanced head and neck cancer that has come back or spread. The study enrolled 123 adults whose tumors have a specific protein (PD-L1…

This early-phase study tested combinations of immunotherapy drugs (atezolizumab and tiragolumab) plus chemotherapy (carboplatin and paclitaxel) in 12 people with advanced head and neck cancer that had not been treated before. The goal was to see if these combinations could comple…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had spread. Participants had not received prior chemotherapy for their advanced disease. The main goal…

This study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…

This early-phase study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to first treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal w…

This study tested whether adding a new drug (RO7200220) to a standard eye injection (ranibizumab) works better than the standard injection alone for people with diabetic macular edema, a condition that causes vision loss. About 187 adults with diabetes and central macular swellin…

This study tested a medicine called risdiplam in 174 adults and children with spinal muscular atrophy (SMA), a genetic disease that weakens muscles. The goal was to see if the drug is safe and how it works in the body. Participants had previously received other SMA treatments. Th…

This study tested a new eye medication called faricimab in 280 people with vision loss from abnormal blood vessels caused by severe nearsightedness. Participants received either faricimab or an existing treatment (ranibizumab) as needed after an initial dose. The goal was to see …

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either chemotherapy alone or chemotherapy plus the immuno…

This study looked at 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from getting worse. The goal was to see how well T-DM1 works in …

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be removed by surgery and had not been treated with systemic therapy before. The goal was to see how safe and effective the combination is. Particip…

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combination shrank tumors or slowed cancer growth. Patients received atezolizumab (an immunotherapy)…

This study tested a new drug called PF-06480605 in 246 adults with moderate to severe ulcerative colitis. Participants received different doses of the drug or a placebo for 12 weeks, then everyone received the active drug for 40 more weeks. The goal was to see if the drug could h…

This study tested whether adding the drug polatuzumab vedotin to a standard chemotherapy regimen (R-GEMOX) helps people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 270 adults took part. The main go…

This study tested an investigational drug called RO7200220 (vamikibart) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. About 394 participants received either the new drug or an active comparator …

This study tested a combination of two drugs, atezolizumab and cabozantinib, against a standard chemotherapy (docetaxel) in 366 people with advanced non-small cell lung cancer that had gotten worse after prior treatments. The goal was to see if the combination helped people live …

This study looked at the long-term safety of the drug tocilizumab (RoActemra/Actemra) in children with a type of arthritis called polyarticular-course juvenile idiopathic arthritis. Seven children who had already finished a main study received the drug every 4 weeks for up to 2 y…

This large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…

This study tested giving immunotherapy drugs before surgery to people with liver cancer that could be removed. The goal was to see if these drug combinations could shrink the tumor or eliminate it before the operation. 62 participants took part in this early-phase trial, which ha…

This study tested several combinations of immunotherapy drugs in 341 people with metastatic pancreatic cancer that had spread. The goal was to see if these treatments could shrink tumors and control the disease. Participants were split into two groups: those who had not yet recei…

This study tested a new combination of drugs (tiragolumab plus atezolizumab and chemotherapy) against the current standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not been treated before. The goal was to see if the …

This study tested several new drug combinations in 281 adults with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if these combinations could safely clear the hepatitis B surface antigen from the blood, which would indicate better disease …

This study looked at how well and how safely ocrelizumab works over a longer time for people with multiple sclerosis (MS). Over 1,000 participants who had already been in earlier Roche studies took part. Researchers tracked disability changes, relapse rates, and side effects to s…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…

This study tested a drug called alogabat in 48 children aged 5-17 with Angelman syndrome (a specific genetic type). The goal was to see how the drug moves through the body and if it is safe. Researchers also looked at brain activity changes to see if the drug works as expected. T…

This study tested whether adding the drug pertuzumab to standard chemotherapy and trastuzumab could help prevent breast cancer from returning after surgery. About 4,800 people with HER2-positive breast cancer took part. The results showed that the three-drug combination improved …

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…

This study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participant…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This study tested a monthly injection called Mircera for people with chronic kidney disease who have anemia (low red blood cells) and are not yet on dialysis. 75 adults received the shot for 3 to 12 months. The goal was to see if it could safely raise and maintain hemoglobin leve…

This study followed 322 adults with moderate to severe rheumatoid arthritis who were starting treatment with tocilizumab (RoActemra/Actemra). Researchers tracked how well the drug controlled disease activity and monitored safety over 12 months in real-world clinics. The goal was …

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment with CDK4/6 inhibitors. Participants received either a standard hormone therapy (fulvestran…

This study tested whether using a person's tumor genetic profile to choose treatment works better than standard chemotherapy for cancer of unknown primary (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either gene-guided therapy …

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye caused by inflammation. 245 adults with this condition took part. The main goal was to see if the drug improves vision by a…

This study tested whether a once-monthly injection of Mircera could keep hemoglobin levels stable in dialysis patients with anemia, compared to the standard epoetin alfa given more often. About 233 adults on dialysis took part. The goal was to see if the monthly shot was as safe …

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with advanced triple-negative breast cancer that returned within a year of initial treatment. About 595 participants received either the drug combo or a placebo plus chemo. …

This study tested a drug called crovalimab to see if it can prevent vaso-occlusive episodes (painful blockages in blood vessels) in people with sickle cell disease. 95 participants received either crovalimab or a placebo alongside their usual treatments. The goal was to reduce th…

This study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication (a combination of pertuzumab and trastuzumab) at home versus in the hospital. About 346 participants were randomly assigned to receive the drug at home…

This study looked at whether people with non-small cell lung cancer prefer getting their medication as a shot under the skin (subcutaneous) or through an IV drip. About 179 adults took part, including those with early-stage cancer after surgery and those with advanced cancer. The…

This study compared a single dose of baloxavir marboxil to a 5-day course of oseltamivir in 100 Chinese children aged 1 to 12 with flu symptoms. The main goal was to check safety, including side effects. Researchers also measured how quickly symptoms like cough and fever improved…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study looked at 70 pregnant women with multiple sclerosis or clinically isolated syndrome who took ocrelizumab before or during early pregnancy. Researchers measured B cell levels in their infants to see if the drug passed through the placenta. The goal was to understand the…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study tested whether using a liquid biopsy (a blood test that looks for cancer DNA) early in the diagnosis process could speed up care for people with advanced lung or gastrointestinal cancer. Researchers compared the timing of diagnosis and treatment recommendations between…